ERBB2 and breast carcinoma: As the first phase III trial to report positive HER2‐low MBC results, the DESTINY‐Breast 04 study changes the treatment landscape for patients with HER2‐low breast cancer, raising the possibility of improving the clinical interpretation of HER2 status from the current dualistic pattern to the three subtypes.